Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Tachibana Y, Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Kijima T, Takayama K. Tachibana Y, et al. Among authors: takayama k. Invest New Drugs. 2024 Aug 21. doi: 10.1007/s10637-024-01467-7. Online ahead of print. Invest New Drugs. 2024. PMID: 39168900
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Takei S, et al. Among authors: takayama k. Front Immunol. 2024 Feb 23;15:1348034. doi: 10.3389/fimmu.2024.1348034. eCollection 2024. Front Immunol. 2024. PMID: 38464519 Free PMC article.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Onoi K, Yamada T, Morimoto K, Kawachi H, Tsutsumi R, Takeda T, Okada A, Tamiya N, Chihara Y, Shiotsu S, Takemura Y, Yamada T, Hasegawa I, Katayama Y, Iwasaku M, Tokuda S, Takayama K. Onoi K, et al. Among authors: takayama k. Target Oncol. 2024 May;19(3):411-421. doi: 10.1007/s11523-024-01045-0. Epub 2024 Mar 11. Target Oncol. 2024. PMID: 38467958
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, Ishida M, Kawachi H, Nakamura R, Nishioka N, Morimoto K, Iwasaku M, Horinaka M, Sakai T, Tokuda S, Takayama K. Matsui Y, et al. Among authors: takayama k. Cancer Sci. 2024 Oct;115(10):3333-3345. doi: 10.1111/cas.16292. Epub 2024 Jul 22. Cancer Sci. 2024. PMID: 39039802 Free PMC article.
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Among authors: takayama k. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Nishioka N, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Masui T, Sai N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Nishioka N, et al. Among authors: takayama k. Front Immunol. 2024 Jul 15;15:1399889. doi: 10.3389/fimmu.2024.1399889. eCollection 2024. Front Immunol. 2024. PMID: 39076994 Free PMC article.
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K. Kawachi H, et al. Among authors: takayama k. Clin Lung Cancer. 2024 Nov;25(7):643-652.e4. doi: 10.1016/j.cllc.2024.07.014. Epub 2024 Jul 25. Clin Lung Cancer. 2024. PMID: 39138106
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.
Kataoka N, Katayama Y, Yamada T, Morimoto K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Nishioka N, Iwasaku M, Tokuda S, Takayama K. Kataoka N, et al. Among authors: takayama k. Transl Lung Cancer Res. 2024 Aug 31;13(8):1929-1937. doi: 10.21037/tlcr-24-190. Epub 2024 Aug 20. Transl Lung Cancer Res. 2024. PMID: 39263030 Free PMC article.
Real-world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications.
Doi T, Ishikawa T, Sakakida T, Itani J, Sone D, Morita R, Kataoka S, Miyake H, Seko Y, Yamaguchi K, Moriguchi M, Sogame Y, Konishi H, Murashima K, Iwasaku M, Takayama K, Itoh Y. Doi T, et al. Among authors: takayama k. Cancer Sci. 2024 Nov;115(11):3729-3739. doi: 10.1111/cas.16329. Epub 2024 Sep 24. Cancer Sci. 2024. PMID: 39315592 Free PMC article.
2,223 results